SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab reports Profit after tax of Rs 16394.00 Mln, in the June 2023 quarter

26 Jul 2023 Evaluate
The sales surged to Rs. 54373.00 millions, up 49.76% for the June 2023 quarter as against Rs. 36306.00 millions during the corresponding quarter previous year.Net Profit witnessed a 228.21% growth almost the double from Rs. 4995.00 millions to Rs. 16394.00  millions  of same quarter last year.OP of the company witnessed a marginal growth to 24613.00 millions from 9829.00 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 54373.00 36306.00 49.76 54373.00 36306.00 49.76 169625.00 144052.00 17.75
Other Income 2336.00 4034.00 -42.09 2336.00 4034.00 -42.09 5913.00 4820.00 22.68
PBIDT 24613.00 9829.00 150.41 24613.00 9829.00 150.41 48061.00 30761.00 56.24
Interest 45.00 98.00 -54.08 45.00 98.00 -54.08 169.00 380.00 -55.53
PBDT 24568.00 9731.00 152.47 24568.00 9731.00 152.47 47892.00 30381.00 57.64
Depreciation 2372.00 2215.00 7.09 2372.00 2215.00 7.09 9232.00 8143.00 13.37
PBT 22196.00 7516.00 195.32 22196.00 7516.00 195.32 38660.00 22238.00 73.85
TAX 5802.00 2521.00 130.15 5802.00 2521.00 130.15 12532.00 6006.00 108.66
Deferred Tax 415.00 1163.00 -64.32 415.00 1163.00 -64.32 3891.00 2080.00 87.07
PAT 16394.00 4995.00 228.21 16394.00 4995.00 228.21 26128.00 16232.00 60.97
Equity 833.00 832.00 0.12 833.00 832.00 0.12 833.00 832.00 0.12
PBIDTM(%) 45.27 27.07 67.21 45.27 27.07 67.21 28.33 21.35 32.69

Dr. Reddys Lab Share Price

1279.70 -13.55 (-1.05%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×